Want to see IN:IKS full AI Analyst Report?
Top Page
Inventurus Knowledge Solutions Limited
(IKS)
Select Model
Select Model
Rating:64Neutral
Price Target:
₹1,900.00
▲(7.92% Upside)
Action:Downgraded
Date:10/02/26
The score is primarily supported by strong recent financial performance (healthy margins, solid earnings growth, and manageable current leverage). Offsetting this are a high P/E valuation and mixed near-term technicals, with only modest positive momentum and price slightly below short-term moving averages.
Positive Factors
Strong revenue and earnings growth
Revenue expansion combined with substantial earnings growth indicates that IKS is scaling its healthcare services platform while converting growth into profit. This strengthens internal funding capacity and supports continued investment in process delivery and technology over the next several quarters.
Negative Factors
Weak operating cash-flow realization
Operating cash flow has converted a smaller share of reported earnings in the last three years, indicating weaker and more volatile cash realization than earlier periods. Persistent conversion pressure could constrain internally funded investment and make earnings quality less dependable.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue and earnings growth
Revenue expansion combined with substantial earnings growth indicates that IKS is scaling its healthcare services platform while converting growth into profit. This strengthens internal funding capacity and supports continued investment in process delivery and technology over the next several quarters.
Read all positive factors
Inventurus Knowledge Solutions Limited (IKS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹286.10B
Dividend YieldN/A
Average Volume (3M)10.15K
Price to Earnings (P/E)37.3
Beta (1Y)0.88
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees9,698
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)45.64
Shares Outstanding171,573,170
10 Day Avg. Volume5,136
30 Day Avg. Volume10,150
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)7.94
Price to Sales (P/S)6.96
P/FCF Ratio37.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,900.00Price Target Upside7.92% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)51.89
Revenue Forecast (FY)₹48.67B
Inventurus Knowledge Solutions Limited Business Overview & Revenue Model
Company Description
Inventurus Knowledge Solutions Limited operates as a technology-enabled healthcare solutions provider. The company offers a care enablement platform that assists physician businesses in outpatient and inpatient care activities in the United States...
How the Company Makes Money
IKS primarily makes money by providing outsourced, healthcare-oriented services to client organizations under contractual arrangements, generating revenue in the form of service fees. Key revenue streams generally include (a) recurring fees for on...
Inventurus Knowledge Solutions Limited Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
72
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.47B | 31.94B | 26.64B | 18.17B | 10.31B | 7.64B |
| Gross Profit | 14.93B | 14.41B | 26.63B | 18.16B | 5.05B | 3.82B |
| EBITDA | 11.93B | 11.54B | 8.09B | 5.61B | 3.89B | 2.98B |
| Net Income | 7.64B | 7.22B | 4.86B | 3.70B | 3.05B | 2.33B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 42.68B | 30.52B | 30.28B | 9.88B | 7.88B |
| Cash, Cash Equivalents and Short-Term Investments | 6.09B | 6.09B | 1.92B | 4.83B | 5.23B | 3.47B |
| Total Debt | 0.00 | 7.53B | 8.56B | 13.11B | 523.46M | 651.92M |
| Total Liabilities | -28.00B | 14.68B | 12.62B | 18.70B | 1.60B | 1.40B |
| Stockholders Equity | 28.00B | 28.00B | 17.90B | 11.58B | 8.29B | 6.47B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 6.00B | 2.93B | 1.77B | 2.79B | 2.22B |
| Operating Cash Flow | 0.00 | 6.32B | 3.18B | 2.10B | 2.88B | 2.33B |
| Investing Cash Flow | 0.00 | -2.15B | 2.44B | -11.41B | -1.56B | -824.48M |
| Financing Cash Flow | 0.00 | -3.65B | -3.89B | 7.80B | -1.52B | -585.10M |
Inventurus Knowledge Solutions Limited Technical Analysis
Neutral
1760.60
Price Trends
1752.58
Negative
1769.93
Negative
1659.04
Positive
Market Momentum
-22.63
Negative
48.09
Neutral
75.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IKS, the sentiment is Neutral. The current price of 1760.6 is above the 20-day moving average (MA) of 1710.23, above the 50-day MA of 1752.58, and above the 200-day MA of 1659.04, indicating a neutral trend. The MACD of -22.63 indicates Negative momentum. The RSI at 48.09 is Neutral, neither overbought nor oversold. The STOCH value of 75.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:IKS.
Inventurus Knowledge Solutions Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹141.61B | 34.30 | ― | 0.38% | 35.84% | -8.11% | |
70 Outperform | ₹331.39B | 90.71 | ― | ― | ― | ― | |
67 Neutral | ₹21.67B | 27.15 | ― | 0.41% | 14.22% | 7.17% | |
64 Neutral | ₹286.10B | 37.33 | ― | ― | ― | ― | |
56 Neutral | ₹162.52B | 86.98 | ― | 0.31% | -5.99% | -60.30% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹147.29B | 41.54 | ― | 0.54% | 16.27% | -23.50% |
* General Sector Average
IN:IKS
Inventurus Knowledge Solutions Limited
1,707.95
71.40
4.36%
IN:INDGN
Indegene Limited
587.65
53.75
10.07%
IN:JUBLPHARMA
Jubilant Pharmova Limited
924.70
-238.38
-20.50%
IN:SYNGENE
Syngene International Ltd.
402.60
-253.29
-38.62%
IN:VIMTALABS
Vimta Labs Limited
484.85
-194.79
-28.66%
IN:SAILIFE
SAI Life Sciences Ltd.
1,559.70
637.45
69.12%
Inventurus Knowledge Solutions Limited Corporate Events
Inventurus Knowledge Solutions Clears All Resolutions at 20th AGM with Strong Shareholder Support
Sep 22, 2026
Inventurus Knowledge Solutions Limited has disclosed the voting results of its 20th Annual General Meeting held on September 21, 2026 via video conferencing, in compliance with SEBI’s Listing Obligations and Disclosure Requirements. The comp...
Inventurus Knowledge Solutions to Engage Investors at Jefferies India Forum
Sep 15, 2026
Inventurus Knowledge Solutions Limited has scheduled an analyst and institutional investor meeting at the 2026 Jefferies India Forum, to be held on Thursday, September 17, 2026, at The Pavilion at Trident, Gurgaon, from 10:00 a.m. to 6:00 p.m. IST...
IKS Enables Digital Access to FY 2025-26 Annual Report and 20th AGM
Aug 28, 2026
Inventurus Knowledge Solutions Limited has notified stock exchanges that it has dispatched letters to members, in line with SEBI Listing Obligations, providing a web link and QR code to access the Annual Report for FY 2025-26 and the notice conven...
Inventurus Knowledge Solutions Publishes Q1 FY27 Unaudited Results in Line with SEBI Norms
Aug 7, 2026
Inventurus Knowledge Solutions Limited has published extracts of its unaudited financial results for the quarter ended June 30, 2026 in the Financial Express and Navshakti, complying with SEBI’s Regulation 47 on listing and disclosure requir...
Inventurus Subsidiary to Monetize Abridge AI Stake in USD 10 Million Deal
Aug 6, 2026
Inventurus Knowledge Solutions Limited has disclosed that its wholly owned subsidiary, Inventurus Knowledge Solutions, Inc., has entered into a stock purchase agreement with Alpha Square Group Fund IV, LP. Under this agreement, it will sell 54,055...
Inventurus Knowledge Solutions Names Independent Director as New Non-Executive Chairman
Aug 5, 2026
Inventurus Knowledge Solutions Limited, a healthcare services and technology provider listed on BSE and NSE, operates from Navi Mumbai and offers knowledge-driven solutions to healthcare providers. The company leverages its IKS Health platform to ...
Inventurus Knowledge Solutions Seals Syndicated Financing for TruBridge Acquisition
Aug 3, 2026
Inventurus Knowledge Solutions Limited operates in the healthcare knowledge and services sector, with its wholly owned U.S. subsidiary Inventurus Knowledge Solutions Inc. pursuing strategic acquisitions to expand its footprint. The group focuses o...
Inventurus Knowledge Solutions backs TruBridge acquisition with USD 603.75 million guarantee and refinancing
Jul 6, 2026
Inventurus Knowledge Solutions Limited has issued a corporate guarantee of up to USD 603.75 million in favour of a consortium of global and Indian lenders, backing facilities of up to USD 575 million to be availed by its wholly owned U.S. subsidia...
Inventurus Knowledge Solutions Secures Financing Framework for TruBridge Acquisition
Jul 3, 2026
Inventurus Knowledge Solutions Limited has detailed the execution of key financing and security agreements tied to its planned acquisition of TruBridge, Inc. by its wholly owned U.S. subsidiary, Inventurus Knowledge Solutions, Inc. The company, al...
Inventurus Knowledge Solutions Tightens Security Package, Trims Loan Size for TruBridge Deal
Jul 2, 2026
Inventurus Knowledge Solutions Limited has revised the financing structure for its pending acquisition of U.S.-based TruBridge, Inc. by reducing the proposed borrowing by its wholly owned subsidiary IKS Inc. from up to USD 670 million to up to USD...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.